Time on boards
- Boards served
- 4
- Current seats
- 4
- Board service
- 10 years
- Director since
- 2023
10 years of board service in total across 4 boards, counting each seat separately. Longest: MaxCyte Inc., 3 years.
MaxCyte Inc.
Director
ALX Oncology Holdings Inc.
Director
BioAge Labs Inc.
Director
LB Pharmaceuticals Inc
Director
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
ALX Oncology Holdings Inc. June 10, 202681.9%
-
BioAge Labs Inc. June 10, 202689.0%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 17, 2026 | MaxCyte Inc. | Grant or award | +30,421 | — | — |
| Jun 25, 2025 | MaxCyte Inc. | Open-market sale | −10,684 | $2.09 | $22,330 |
| Jun 18, 2025 | MaxCyte Inc. | Grant or award | +29,210 | — | — |
| Dec 2, 2024 | ALX Oncology Holdings Inc. | Open-market purchase | +30,000 | $1.55 | $46,500 |
| Jun 11, 2024 | MaxCyte Inc. | Grant or award | +21,367 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.